Allogenetics Appoints Dr. Jeroen Rovers as Chief Medical Officer to Advance ALG-115 Toward Clinical Trials in Lung Transplantation
核心洞察
Allogenetics (搜索) has appointed Jeroen Rovers, MD, PhD, as Chief Medical Officer, bringing over 20 years of biotech and pharmaceutical development experience in immunology and transplantation.
Dr. Rovers will lead the clinical advancement of ALG-115 (搜索), an ex vivo donor-organ gene therapy designed as a one-time treatment to prevent graft rejection (搜索) in lung transplantation.
ALG-115 (搜索) aims to modify the donor organ before transplantation to prevent rejection at its source while preserving full immune competence, potentially reducing or eliminating the need for lifelong immunosuppression.
Hanover, Germany, July 21, 2026 – Allogenetics (搜索) today announced the appointment of Jeroen Rovers, MD, PhD, as Chief Medical Officer, strengthening its executive team at a pivotal moment as the company prepares to advance its lead candidate, ALG-115 (搜索), toward clinical evaluation in lung transplantation.
Dr. Rovers brings more than 20 years of experience in biotechnology and pharmaceutical product development, with deep expertise across hematology, immunology, transplantation, and emerging therapies. He succeeds Prof. Dr. Rainer Blasczyk, who will continue to support the company as a Clinical Advisor.
"Jeroen is a highly respected clinical development leader with precisely the experience Allogenetics (搜索) needs at this important inflection point toward clinical translation," said Oliver Ernst, PhD, Chief Executive Officer of Allogenetics. "His track record and hands-on experience in advancing innovative therapies through proof-of-concept, pivotal development and regulatory interactions will be instrumental as we prepare to bring our lead candidate ALG-115 (搜索) to lung transplant patients."
A Novel Approach to Graft Rejection (搜索)
ALG-115 (搜索) is an ex vivo donor-organ gene therapy candidate designed as a one-time treatment to modify the donor organ before transplantation. The therapy aims to prevent donor organ rejection at its source while retaining full immune competence, addressing one of the most persistent challenges in transplant medicine.
"Despite the success of organ transplantation, patients continue to face the burden of lifelong immunosuppression and its associated risks," said Dr. Rovers. "The company's approach is compelling because it addresses graft rejection (搜索) at the level of the donor organ, before transplantation. I am excited to join this exceptional team as we drive the clinical development of ALG-115 (搜索) in lung transplantation forward to improve graft survival and quality of life for lung transplant patients."
Allogenetics (搜索)' proprietary technology platform enables a calibrated knockdown of cell-surface antigen presentation – specifically MHC class I and II (搜索) – to evade graft rejection (搜索) while retaining full immune competence. The company's goal is to reduce and potentially eliminate the need for lifelong immunosuppression, thereby improving graft survival and patient quality of life.
Dr. Rovers' Clinical Development Track Record
Dr. Rovers most recently served as Chief Medical Officer at Mendus (搜索), where he led clinical strategy and operations for multiple cell-based oncology programs, advancing novel therapies through proof-of-concept and pivotal trial preparation. Prior to that, he was Chief Medical Officer and Senior Vice President at Kiadis Pharma (搜索), where he directed the development of ATIR, a T-cell depleted donor infusion for patients with hematological malignancies undergoing bone marrow transplantation. His responsibilities at Kiadis included the initiation of Phase 2 and pivotal Phase 3 trials and the submission of a marketing authorization dossier to the European Medicines Agency.
Earlier in his career, Dr. Rovers held senior clinical and medical affairs roles at Organon, Wyeth Pharmaceuticals, and Biolitec Pharma. He holds an MD and PhD from Leiden University and has authored more than 20 publications in oncology, immunotherapy, and photodynamic therapy.
Pipeline and Future Direction
Building on compelling proof-of-concept data in animal models, Allogenetics (搜索) plans to bring its novel organ-agnostic approach into human clinical trials, starting with lung and kidney grafts. The company's mission is to enable longer and healthier lives for transplant patients by fine-tuning the balance between immune tolerance and protection, while also addressing the global organ shortage crisis through its immune-tolerance platform.
Ernst also acknowledged the contributions of the outgoing CMO: "I want to express my sincere thanks to Rainer, whose pioneering research and contribution as co-founder laid the scientific foundation for the company."